New patient-level data will facilitate more efficient clinical trial design
Category Archives: AZBio News
OncoMyx Presents at AACR First Data Showing Multi-Armed Myxoma Virotherapy Can Modulate Anti-Tumor Immune Response
OncoMyx’s multi-armed myxoma virotherapy upregulates genes associated with immune response and shows modulation of the immune response to favor anti-tumor immunity
vMYX-hIL-12/Dec produces functional protein (hIL-12) from transgenes in vivo and in a dose and time responsive in vitro and has demonstrated anti-tumor efficacy in a xenograft human lung cancer model
Quantitative systems pharmacology modeling suggests IV administration of multi-armed myxoma virotherapy to fall within known safety margins at the planned doses of oncolytic immunotherapiesContinue reading
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
– Trodelvy Significantly Reduced the Risk of Death by 49% Compared with Single-Agent Chemotherapy in the Phase 3 ASCENT Study –
– Trodelvy is Under Regulatory Review in the EU and in the United Kingdom, Canada, Switzerland and Australia as Part of Project Orbis –
ASU is among the leaders in patents granted, start-ups launched
Tempe, Ariz., April 8, 2021 – Arizona State University, through Skysong Innovations, continues to achieve high rankings in technology transfer metrics. The latest read on this is a survey by the Association of University Technology Managers (AUTM). According to AUTM’s most recent survey (fiscal year 2019), ASU was fourth in patents granted, fourth in startups companies launched and third in inventions disclosed when compared to other universities without a medical school.
Life365 Continues to Build Upon Its Hospital@Home Product Offering with Eat Fit Go Partnership
SCOTTSDALE, AZ, April 6, 2021— Life365, a leading virtual care platform provider, announced its partnership with EAT FIT GO Wellness, a healthy lifestyles company that empowers wellbeing from the inside out with premium, convenient and healthy nutrition. EAT FIT GO specializes in ready to heat and serve healthy prepackaged meals designed to be affordable, convenient and nutritious.
COVID-19 Testing Comes to Arizona’s Schools
Arizona’s leading diagnostic testing lab, Sonora Quest Laboratories, is teaming up with Ginkgo Bioworks, Inc. (“Ginkgo”), the organism company, a Boston-based biotechnology firm committed to supporting the fight against COVID-19, to provide pooled COVID-19 testing to K-12 school districts throughout Arizona. Continue reading
Indoor Drive-Thru Vaccination Site Opens at Dexcom in Mesa
“At Dexcom, our mission is to help improve the health of others, so when asked if we could provide our facility for an indoor mass-vaccination site, we didn’t hesitate,” said Jim Kasselmann, senior director of manufacturing in Mesa for Dexcom. “We are proud to manufacture our products in Mesa, and anytime we can help our local community, that is what we will do.”Continue reading
Regenesis Biomedical Introduces the New Provant Infinity
Scottsdale, Arizona based, Regenesis Biomedical, Inc. has launch the new Provant® Infinity system that is available purchase for home use when prescribed by a health professional. Outcomes with Provant Therapy are documented in journal articles, white papers, and case reports. Provant relieves pain in several post-operative conditions, including orthopaedic surgery, joint replacement, amputation, rotator cuff repair, back surgery, hernia repair, debridement, hand and foot surgeries, and neuropathy.Continue reading
Banner Alzheimer’s Institute gets $27.5M NIH grant for genetic risk study
Banner Alzheimer’s Institute (BAI) has received a grant expected to total $27.5 million over five years from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to further investigate biological and cognitive changes preceding the onset of memory and thinking problems in people at different levels of genetic risk for Alzheimer’s disease. Led by researchers from Banner and Mayo Clinic in Arizona, the five-year grant will study healthy people with six forms of the apolipoprotein E (APOE) gene, the major genetic risk factor for Alzheimer’s disease, create a shared scientific resource of data and biological samples to support a wide range of future studies, and help to advance the understanding, treatment, and prevention of Alzheimer’s disease.Continue reading
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma
Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma
In the pivotal KarMMa trial, the majority (72%) of patients achieved rapid, deep and durable responses1
Safety profile of Abecma is well-established and predictable including cytokine release syndrome and neurologic toxicities that are mostly low-grade with early onset and resolution1